1622MO Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study — John Zalcberg (2020) | RDL Network
1622MO Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
Margaret von Mehren, Michael C. Heinrich, Suzanne George, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, César Serrano, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Julie Nicole Meade, V. Reichert, Kelvin Shi, Rodrigo Ruiz‐Soto, Jean Yves Blay
Michael C. Heinrich, Suzanne George, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, C Pardo Serrano, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Claus Becker, Julie Nicole Meade, Rodrigo Ruiz‐Soto, Margaret von Mehren, Jean Yves Blay
Sebastian Bauer, Michael C. Heinrich, Suzanne George, John Zalcberg, César Serrano, Hans Gelderblom, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Julie Meade, Ying Su, Rodrigo Ruiz‐Soto, Jean Yves Blay, Margaret von Mehren, Patrick Schöffski
John Zalcberg, Michael C. Heinrich, Suzanne George, Sebastian Bauer, Patrick Schöffski, César Serrano, Robin L. Jones, Hans Gelderblom, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Neeta Somaiah, Julie Nicole Meade, V. Reichert, Kelvin Shi, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Margaret von Mehren, Jean Yves Blay
César Serrano, Michael C. Heinrich, Suzanne George, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, J. Meade, V. Reichert, Kelvin Shi, Jean Yves Blay, Margaret von Mehren
Discussion(0)
No comments yet. Be the first to comment.